Sign In
Buy INCY
$97.98
+5.74 (+6.22%)
At Close: Jun 03, 2026
MorphoSys and Incyte Announce Acceptance by Health Canada of the New Drug Submission for Tafasitamab
04:30pm, Tuesday, 12'th Jan 2021
PLANEGG/MUNICH, GERMANY and MONTREAL, QC / ACCESSWIRE / January 12, 2021 / MorphoSys AG (FSE:MOR; Prime Standard Segment; MDAX & TecDAX; NASDAQ:MOR) and Incyte (NASDAQ:INCY) today announced that Healt
Incyte (INCY) Partners With Cellenkos for Myelofibrosis Treatment
09:47am, Thursday, 31'st Dec 2020
Incyte (INCY) enters into a collaboration with Cellenkos to evaluate the combination of Jakafi and CK0804 in patients with myelofibrosis.
Why These Health Care Stocks Are Moving Today
02:03pm, Wednesday, 30'th Dec 2020
Altimmune (NASDAQ: ALT) shares were trading higher Wednesday after the company announced it began a multinational Phase 2 clinical trial of HepTcellTM for the treatment of chronic Hepatitis B. Altimm
Incyte and Cellenkos Enter into Global Development Collaboration Agreement for CK0804
07:30am, Wednesday, 30'th Dec 2020
WILMINGTON, Del.--(BUSINESS WIRE)---- $INCY--Incyte and Cellenkos Enter into Global Development Collaboration Agreement for CK0804
WILMINGTON, Del.--(BUSINESS WIRE)---- $INCY--Incyte Announces Results of Phase 3 RUXCOVID Study of Ruxolitinib (Jakafi®) as a Treatment for Patients with COVID-19 Associated Cytokine Storm
INDIANAPOLIS, Dec. 11, 2020 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) and Incyte (NASDAQ: INCY) announced today that The New England Journal of Medicine has published peer-reviewed results fro
Incyte to Present at Upcoming Investor Conference
08:00am, Wednesday, 09'th Dec 2020
WILMINGTON, Del.--(BUSINESS WIRE)--Incyte (Nasdaq:INCY) announced today that it will present at the 39th Annual J. P. Morgan Virtual Healthcare Conference on Monday, January 11, 2021 at 7:30 a.m. EST.
WILMINGTON, Del. & PLANEGG/MUNICH, Germany--(BUSINESS WIRE)---- $INCY #ASH20--Data Evaluating Tafasitamab with and without Lenalidomide in Combination with R-CHOP in Patients with DLBCL Presented at A
WILMINGTON, Del.--(BUSINESS WIRE)---- $INCY #ASH20--First Data from REACH3 Show Ruxolitinib (Jakafi) Significantly Improved Outcomes in Patients with Steroid-Refractory or Steroid-Dependent cGVHD
Incyte: Wait No More - Time To Buy
09:15am, Wednesday, 02'nd Dec 2020
Back on Dec. 29, 2019, I published an article here on Seeking Alpha, "Incyte Corporation: Wait And Watch." Those who waited and watched would have been well rewarded, with significantly lower share pr
Baricitinib Receives Emergency Use Authorization from the FDA for the Treatment of Hospitalized Patients with COVID-19
05:20pm, Thursday, 19'th Nov 2020
INDIANAPOLIS, Nov. 19, 2020 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) and Incyte (NASDAQ: INCY) announced today that the U.S. Food and Drug Administration (FDA) issued an Emergency Use Authori
Incyte Corporation (INCY) CEO Hervé Hoppenot on Q3 2020 Results - Earnings Call Transcript
02:53pm, Thursday, 05'th Nov 2020
Incyte Corporation (INCY) CEO Hervé Hoppenot on Q3 2020 Results - Earnings Call Transcript
More than 40 Abstracts from Incyte's Oncology Portfolio Accepted for Presentation at the 62nd Annual ASH Virtual Meeting
03:55pm, Wednesday, 04'th Nov 2020
WILMINGTON, Del.--(BUSINESS WIRE)---- $INCY--More than 40 Abstracts from Incyte's Oncology Portfolio Accepted for Presentation at the 62nd Annual ASH Virtual Meeting
ACR 2020: Lilly and Incyte Highlight Positive Data for Olumiant® in Rheumatoid Arthritis
02:00pm, Monday, 02'nd Nov 2020
INDIANAPOLIS, Nov. 2, 2020 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) and Incyte (NASDAQ: INCY) announced today positive data for Olumiant® (baricitinib) will be presented at ACR Convergence 2
Week In Review: CStone Out-Licenses Ex-China Rights To 2 Immunotherapies In $1.3 Billion Deal
02:28pm, Sunday, 01'st Nov 2020
CStone Pharma out-licensed global rights (ex-China) for two immuno-oncology assets to US-based EQRx in a $1.3 billion agreement. CASI Pharma in-licensed China rights to a novel antibody checkpoint rec
